AGG Talks: Government Insight for Life Sciences Leaders Podcast Series

Our podcast series hosts strategic conversations at the center of life sciences, law, and policy. During each episode, AGG’s former government attorneys bring firsthand knowledge and updates from their respective agencies — such as the HHS and DOJ — and examine how the latest regulatory developments and enforcement trends impact life sciences organizations. These insider insights, paired with the practical experience of AGG’s Life Sciences team, offer the life sciences industry a map of the road ahead in today’s regulatory environment.

AGG Talks: Government Insight for Life Sciences Leaders Podcast Series is a business podcast hosted by Arnall Golden Gregory LLP, with 13 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Arnall Golden Gregory LLP hosts AGG Talks: Government Insight for Life Sciences Leaders Podcast Series, a business show with 13 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  AGG Talks: Government Insight for Life Sciences Leaders Podcast Series

  Patient Assistance Programs and the False Claims Act: Enforcement Trends and Compliance Risks for Life Sciences Companies

  Jan 14, 202623 minS0

  <p>In this episode, AGG Life Sciences co-chair Alan Minsk is joined by AGG Healthcare and Life Sciences partner David Blank, former Senior Counsel at the HHS Office of Inspector General ("OIG"), for an in-depth discussion on Patient Assistance Programs ("PAPs"), the False Claims Act ("FCA"), and evolving enforcement priorities impacting life sciences companies.<br/><br/>Drawing on his experience at OIG and advising companies today, David unpacks how DOJ and OIG are approaching market access, patient support, and reimbursement arrangements — including PAPs, sponsored genetic testing, and vendor relationships. He explores enforcement trends, the role of data analytics and whistleblowers, an...

  ListenShow Notes
• 

  Episode #3

  How Medicare Regulations Could Affect Access to Gender-Affirming Care: Implications for Life Sciences Companies

  Nov 14, 202517 minS2

  <p>In this episode, AGG Life Sciences co-chair Alan Minsk and Healthcare partner Andrew Tsui examine how the Centers for Medicare & Medicaid Services ("CMS") may apply the Medicare Conditions of Participation ("COPs") to emerging areas of healthcare, including gender-affirming care — and what those developments could mean for pharmaceutical companies and drug manufacturers.<br/><br/>They discuss how updates to COPs can impact operational requirements for healthcare providers and influence compliance considerations. Andrew also examines how these changes could ripple through payor markets, pharmaceutical coverage, and the broader regulatory framework affecting the life sciences industry.<br/><br/>With his experience as fo...

  ListenShow Notes
• 

  Episode #2

  DOJ’s Shifting Enforcement: CPB Disbanding, Counterfeit Drug Focus, and Gender-Affirming Care Investigations

  Oct 7, 202517 minS2

  <p>In this episode, Alan Minsk, AGG Food & Drug practice chair and Life Sciences co-chair, and Gabe Scannapieco,  Litigation and Healthcare partner and Life Sciences co-chair, unpack recent shifts at the U.S. Department of Justice that could reshape regulatory risk for life sciences organizations. <br/>       <br/>They discuss the disbanding of DOJ’s Consumer Protection Branch ("CPB") and what the loss of centralized oversight could mean for coordinated investigations in the industry. The conversation also examines DOJ’s intensified focus on counterfeit drugs and its targeting of the entire supply chain in collaboration with FDA, DEA, and other agencies.<br/>     ...

  ListenShow Notes
• 

  Episode #1

  HHS Policy Changes, Supreme Court Rulings, and the DOJ-HHS False Claims Act Working Group

  Aug 15, 202513 minS2

  <p>In this episode, Alan Minsk, AGG Food & Drug practice chair and Life Sciences co-chair, and Brian Stimson, co-chair of the Healthcare practice and former acting general counsel and principal deputy general counsel of the U.S. Department of Health and Human Services ("HHS"), discuss three recent developments affecting life sciences companies.<br/>       <br/>Alan and Brian review the HHS policy-making process, including the formal requirements for changing policies that have undergone notice-and-comment rulemaking. They also examine the Supreme Court’s decision in Trump v. CASA, which limits nationwide injunctions and places greater responsibility on companies to take direct action to pro...

  ListenShow Notes
• 

  Episode #9

  Tell Me Lies, Tell Me Sweet Little Lies: FDA Is Not My Only Potential Headache When It Comes to Product Promotion

  Mar 23, 202329 minS1

  <p>In this episode, Alan G. Minsk, AGG Food & Drug team leader, and Anuj Desai, AGG Intellectual Property partner and head of Trademarks, discuss recent developments that remind our audience in the food and drug space that FDA is not the only regulatory agency that’s keeping an eye on the marketplace. Alan and Anuj look at how NAD, a BBB program that supports advertising self-regulation, recently addressed a challenge in the prescription drug space. They also talk about how FTC investigative priorities in the past several months may be relevant to the food and drug/life sciences space.<br/><br...

  ListenShow Notes

Recent guests on AGG Talks: Government Insight for Life Sciences Leaders Podcast Series. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.